Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Frank QianSection of Cardiovascular Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.ORCID 0000-0002-5579-3410
Yidie LinDepartment of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.ORCID 0000-0001-9483-701X
Yue SunDepartment of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
Paul S AisenAlzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA, USA.ORCID 0000-0002-2896-5838
Christine M AlbertDepartment of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-2081-1121
William J AronsonDepartment of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.ORCID 0000-0003-2107-5362
Abdul Aziz A AsbeutahDepartment of Medicine, Division of Cardiovascular Medicine, University of Wisconsin-Madison Hospitals and Clinics, Madison, WI, USA.ORCID 0000-0001-7980-2580
Heike A Bischoff-FerrariDepartment of Aging Medicine, University of Basel, Felix Platter, Basel, Switzerland.ORCID 0000-0002-4554-658X
Matthew J BudoffDepartment of Medicine, Lundquist Institute at Harbor-UCLA Medical Center, CA, USA.ORCID 0000-0002-9616-1946
Nicholas R BurnsSchool of Psychology, University of Adelaide, Adelaide, Australia.ORCID 0000-0003-3456-6734
Cecilia A CardenasDivision of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Cynthia M CarlssonDivision of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0001-5743-1563
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute/National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-0999-9802
Neal J CohenBeckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, United States.ORCID 0000-0001-5556-0417
Léopold K FezeuUniversité Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Centre for Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), F-93017 Bobigny, France.ORCID 0000-0002-7589-3179
Amana LiddellDepartment of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA.ORCID 0009-0001-1296-2093
Pilar GalanUniversité Sorbonne Paris Nord and Université Paris Cité, INSERM, INRAE, CNAM, Centre for Research in Epidemiology and StatisticS (CRESS), Nutritional Epidemiology Research Team (EREN), F-93017 Bobigny, France.ORCID 0000-0003-1706-3107
Mark A HullLeeds Institute of Medical Research, University of Leeds, St James's University Hospital, Leeds, UK.ORCID 0000-0001-7414-1576
Tsuo-Hung LanTsaotun Psychiatric Center, Ministry of Health and Welfare, Nantou, Taiwan.ORCID 0000-0002-2796-1026
Pan-Yen LinDepartment of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.ORCID 0000-0002-0376-4562
Alexia MengelbergSchool of Psychology, Massey University Wellington, Wellington, New Zealand.ORCID 0000-0001-6746-7092
Anne-Marie MinihaneDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.ORCID 0000-0001-9042-4226
Joseph F QuinnDepartment of Neurology, Oregon Health and Science University, Portland, USA.ORCID 0000-0001-7305-2256
Thomas A B SandersDepartment of Nutritional Sciences, King's College London, London, UK.ORCID 0000-0001-9529-095X
David A SchoenfeldDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1948-3711
Andrew ScholeySchool of Psychology, Northumbria University, Newcastle-upon-Tyne, UK.ORCID 0000-0003-4484-5462
Kirsty SprangeNottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0001-6443-7242
Kuan-Pin SuDepartment of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.ORCID 0000-0002-4501-2502
Christopher H van DyckDepartment of Psychiatry, Yale University, New Haven, Connecticut, USA.ORCID 0000-0003-1779-097X
Carol A Van HulleDivision of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID 0000-0002-2288-8819
David VauzourDepartment of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia, Norwich, UK.ORCID 0000-0001-5952-8756
Claire WeberDivision of Epidemiology and Clinical Applications, National Eye Institute/National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-2352-8479
Francine K WeltyDivision of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215.ORCID 0000-0002-0091-406X
Gary WittertSchool of Medicine, University of Adelaide, Adelaide, Australia.ORCID 0000-0001-6818-6065
Salim YusufPopulation Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-4776-5601
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Multidisciplinary Training Program in Cardiovascular EpidemiologyT32HL125232 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Matthew G. Nayor, Vanessa Xanthakis · 2016 to 2026
Background: Recent meta-analyses of randomized controlled trials (RCTs) have raised concerns that treatment with omega-3 fatty acids may increase risk of atrial fibrillation (AF). However, these meta-analyses included at most eight trials. The aim of this current meta-analysis was to expand the search by including other eligible omega-3 RCTs with AF incidence data, incorporating both published and unpublished data. Methods: Eligible studies were RCTs investigating daily doses of ≥500 mg/d of docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA). Additional inclusion criteria included ≥12 months treatment with EPA/DHA, participants ≥ 50 years of age, and where possible, the absence of known AF/atrial flutter at baseline. The primary outcome was occurrence of new-onset AF. Our primary hypothesis was that risk for AF would simultaneously depend on both omega-3 dose (above or below 1500 mg/d) and background cardiovascular disease (CVD) risk status, and that their combined impact on AF risk would be synergistic. Results: A total of 34 RCTs (36 datasets; n=114,326) were included in this meta-analysis. Only studies including patients at high-risk for CVD who were treated with high-doses of EPA/DHA (>1500 mg/day) showed a statistically significant increase in AF risk with a pooled odds ratio (OR) of 1.48 (95% CI, 1.21-1.81) and an absolute risk difference of 0.8% (0.40-1.1%). None of the other three groups showed statistically significant levels of AF risk (ORs 1.07 (high risk, low dose), 1.06 (low risk, low dose) and 0.95 (low risk, high dose). Conclusion: This meta-analysis suggests that treatment with EPA/DHA is most likely to increase risk for AF in patients at high-risk for CVD who are treated with high doses of EPA/DHA. The risk for AF should be balanced against the benefits of EPA/DHA in making treatment decisions.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.